Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)

Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) / Van Wijmeersch, B; Barone, D; Broadley, S; Dive, D; Hupperts, RMM; Lycke, J; Massacesi, L; Montalban, X; Naismith, RT; Pandey, K; Schippling, S; Vermersch, P; Chung, L; Daizadeh, N; Rodriguez, CE; Nakamura, K; Wiendl, H. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - STAMPA. - 24:(2018), pp. 488-489.

Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)

BARONE, DOMENICA;Massacesi, L;
2018

Abstract

Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)
2018
Van Wijmeersch, B; Barone, D; Broadley, S; Dive, D; Hupperts, RMM; Lycke, J; Massacesi, L; Montalban, X; Naismith, RT; Pandey, K; Schippling, S; Vermersch, P; Chung, L; Daizadeh, N; Rodriguez, CE; Nakamura, K; Wiendl, H
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1177415
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact